Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 16-19 September 2013

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 16-19 September 2013
 
This press release provides an overview of the opinions adopted at the September 2013 meeting of the Committee for Medicinal Products for Human Use (CHMP) and other important outcomes. This month, the Committee recommended 11 new medicines for approval – the most medicines recommended for approval at a CHMP meeting so far in 2013.
 
Eleven new medicines recommended for approval
 
The CHMP recommended the approval of two medicines for cancer: Kadcyla for the treatment of metastatic breast cancer and Xofigo for the treatment of castration-resistant prostate cancer.
 
The Committee also gave positive recommendations for three medicines intended to treat neurological disorders: Abilify Maintena for the treatment of schizophrenia, Memantine Accord, a generic medicine, for the treatment of Alzheimer's disease and Levodopa Carbidopa Entacapone Sandoz, which was submitted as a so-called informed consent application, for the treatment of adult patients with Parkinson's disease.
 
The CHMP also recommended that Vitekta should be granted marketing authorisation for the treatment of human immunodeficiency virus‑1 (HIV‑1) infection in adults who are infected with HIV‑1 without known mutations associated with resistance to elvitegravir.
 
Invokana received a positive opinion for marketing authorisation for the treatment of type 2 diabetes mellitus.
 
NovoEight was recommended for marketing authorisation for the treatment of haemophilia A and Relvar Ellipta received a positive opinion from the Committee for the treatment of asthma and chronic obstructive pulmonary disorder (COPD).
 
The vaccine Fluenz Tetra was recommended for a marketing authorisation for the prevention of influenza in children and adolescents 24 months to less than 18 years of age.
 
The Committee recommended that Lidocaine / Prilocaine Plethora should be granted marketing authorisation for the treatment of primary premature ejaculation in adult men.
 
Four recommendations on extensions of therapeutic indications
 
The CHMP recommended an extension to the existing indications for Cimzia, Kineret, Votubia and Yervoy.
 
Two re-examination procedures for referral opinions started
 
The CHMP started a re-examination procedure for dihydroergotoxine, one of the medicines included in the Article-31 referral procedure on ergot derivatives. The other ergot derivatives in this referral are not included in this re-examination.
 
The Committee also started a re-examination procedure for metoclopramide-containing medicines.
 
CHMP welcomes new members
 
At the September CHMP, Daniel Brasseur, former Chair of the Paediatric Committee (PDCO), replaced Pieter Neels as the Belgian CHMP member. Before joining the PDCO, Dr Brasseur was chair of the CHMP. Pieter de Graeff replaced Barbara van Zwieten-Boot as the new CHMP member from the Netherlands, and Greg Markey became the new CHMP member from the UK, replacing Ian Hudson, who was recently appointed Chief Executive of the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA).
 
More information on these and all other outcomes of this month's meeting are available on the Agency's website at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/09/news_detail_001889.jsp&mid=WC0b01ac058004d5c1
 
 
 
 
Contact our press officer
 
Monika Benstetter
Tel. +44 (0)20 7418 8427
 

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.